Trifecta-Kidney cfDNA-MMDx Study
ConditionKidney Transplant Rejection
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorUniversity of Alberta
About this trial
Demonstrate the relationship between DD-cfDNA levels and HLA antibodies in blood, and the Molecular Microscope® (MMDx) Diagnostic System results in indication biopsies.
Eligibility criteria
Qualifiers
All kidney transplant recipients undergoing a kidney biopsy for clinical indications, as determined by their physician or surgeon, will be eligible to enroll in the study.
Disqualifiers
Patients will be excluded from the study if they decline participation or are unable to give informed consent or multiple organ recipients.
Trial design
Treatments tested in this trial
- MMDx
- Prospera
- HLA antibody
Treatment groups
300 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov